GSK's swine flu vaccine launched

Pandemrix is one of two vaccines now available for swine flu prophylaxis in high-risk patients.

Pandemrix should be used in accordance with official guidance.

The dose recommendations are based on safety and immunogenicity data available from the administration of AS03-adjuvanted vaccine containing 3.75 microgram HA derived from A/Vietnam/1194/2004 (H5N1) in adults including the elderly. Half the dose was given to children 3-9 years old and doses were given on days 0 and 21.

Limited immunogenicity data suggest that a second dose may not be required in healthy adults aged 18-60 years.

View Pandemrix drug record

Further information: GSK


To sign up for the MIMS monthly news update, register at www.mims.co.uk/bulletins.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

New rapidly acting insulin launched

New rapidly acting insulin launched

Lyumjev is a new 'ultra rapidly acting' formulation...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Statin prescribing 'commonly breaching NICE guidance'

Statin prescribing 'commonly breaching NICE guidance'

Prescribing of suboptimal statin regimens is 'extremely...